Ratio Therapeutics, Inc. has closed a $70 million Series C financing, bringing total capital raised to over $240 million. The round included participation from existing investors Duquesne Family Office and Bristol Myers Squibb, along with new investors Catalio Capital Management, Eli Lilly and Company, and Wasatch Group.
Ratio plans to use the funding to advance its ongoing ATLAS study evaluating its lead radiotherapeutic asset [Ac-225]RTX-2358 in advanced sarcomas, and to move its next-generation RLT candidate into the clinic. The company also plans to expand its discovery pipeline into new oncology targets and strengthen its manufacturing capabilities, anchored by its vertically integrated site in Utah.
KEY QUOTES:
“This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead. As we march the ATLAS trial forward and prepare for our 5th IND filing, these proceeds are instrumental across the development and ultimately the supply of our targeted and PK-optimized radiopharmaceuticals.”
Dr. Jack Hoppin, CEO, Ratio Therapeutics
“Ratio is a leader in radiopharmaceutical innovation and it has backed up science with execution, hitting clinical milestones, deepening strategic partnerships, and building the manufacturing infrastructure this modality demands. Our investment reflects our strong conviction in Ratio’s platform and its potential to change outcomes for patients.”
Sue Meng, Managing Director, Duquesne Family Office
